New DNA Vaccines Data Have Been Reported by Researchers at Karolinska University (Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination)
By a News Reporter-Staff News Editor at Life Science Weekly -- A new study on Biotechnology is now available. According to news reporting from Stockholm, Sweden, by NewsRx journalists, research stated, "We have investigated the ability of hepatitis C virus non-structural (NS) 3/4A-DNA-based vaccines to activate long-term cell-mediated immune responses in mice. Wild-type and synthetic codon optimized (co) NS3/4A DNA vaccines have previously been shown to be immunogenic in mice, rabbits and humans, although we have very poor knowledge about the longevity of the immune responses primed."
The news correspondents obtained a quote from the research from Karolinska University, "We therefore analyzed the functionality of primed NS3/4A-specific immune responses in BALB/c (H-2(d)) and/or C57BL/6J (H-2(b)) mice 1, 2, 3, 4, 6, 12 and 16 months after the last immunization. Mice were immunized one, two, three or four times using gene gun delivery to the skin or by intramuscular administration. Immunological responses after immunization were monitored by protection against in vivo challenge of NS3/4A-expressing syngeneic tumor cells. In addition, functionality of the NS3/4A-specific T cells was analyzed by a standard cytotoxicity assay. First, we identified a new unique murine H-2(d)-restricted NS3/4A cytotoxic T lymphocyte (CTL) epitope, which enabled us to study the epitope-specific immune responses. Our results show that the coNS3/4A vaccine was highly immunogenic by determination of interferon-gamma/tumor necrosis factor-a production and lytic cytotoxic T cells, which could efficiently inhibit in vivo tumor growth. Importantly, we showed that one to four monthly immunizations protected mice from tumor development when challenged up to 16 months after the last immunization. When determining the functionality of NS3/4A-specific T cells in vitro, we showed detectable lytic activity up to 12 months after the last immunization. Thus, NS3/4A-based DNA vaccines activate potent cellular immune responses that are present and function in both BALB/c and C57BL/6J mice up to 12-16 months after the last immunization."
According to the news reporters, the research concluded: "The induction of long-term immunity after NS3/4A DNA immunization has not been shown previously and supports the use of NS3/4A in hepatitis C virus vaccine compositions."
For more information on this research see: Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. Gene Therapy, 2014;21(8):739-750. Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Gene Therapy - www.nature.com/gt/)
Our news journalists report that additional information may be obtained by contacting G. Ahlen, Karolinska Univ, Huddinge Hosp, Karolinska Inst, Dept. of Lab MedDiv Clin Microbiol, S-14186 Stockholm, Sweden. Additional authors for this research include F. Holmstrom, A. Gibbs, M. Alheim and L. Frelin (see also Biotechnology).
Keywords for this news article include: Stockholm, Sweden, Europe, Biotechnology, DNA Research, DNA Vaccines, Synthetic Vaccines, Viral DNA
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC